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ABSTRACT 
Overweight and obesity are major risk factors for a number of chronic diseases, including 
diabetes, cardiovascular diseases and hypertension. Once considered a problem only in high 
income countries, overweight and obesity are now dramatically on the rise in low and middle-
income countries, particularly in urban settings. A person with a BMI of 30 or more is generally 
considered obese. A person with a BMI equal to or more than 25 is considered overweight. 
Medodhatuvridhi causes Snigdhata of Shareera, Udara-parshvavridhi, Kasa, Shwasa, Hikka and 
Daurgandhya of Shareera. The Medovaha Srotas moola means the organs closely related to the 
functions of Medodhatu or the important sites related to beginning or ending of the channels of 
Medodhatu. The Acharya (Charaka, Sushruta and Vagbhata) considered Vrikka as Moola of 
Medovaha Srotas and also considered Vapavahana, Kati and Mamsa as second Moola 
respectively. The present study was conducted on 30 clinically diagnosed patients of 'Medoroga' 
(Obesity). The patients of ‘Medoroga’ (Obesity) were randomly divided into three groups of 10 
patients in each. In Group A, 10 patients were treated with ‘Navakaguggulu’ 2 tab (each tab. of 
500mg) three times a day with lukewarm water for 30 days. In Group B, 10 patients were 
treated with ‘Triphala Kwatha’ 50ml two times a day (morning and evening) for 30 days and in 
Group C, 10 patients were treated with ‘Navakaguggulu’ 2 tab (each tab. of 500 mg) three times 
a day with lukewarm water and ‘Triphala Kwatha’ 50ml two times a day (morning and evening) 
for 30 days. After completion of trial, Group C has shown the best result followed by Group A 
and B while in lab parameters Group A has shown highly significant result only in Triglyceride 
level. Similarly Group Cprovided better results in majority of the parameters. 
KEYWORDS: Obesity, Medoroga, Navakaguggulu, Triphala Kwatha. 
INTRODUCTION 
Medoroga is a condition in which there is 
excessive accumulation of Meda Dhatu in the body. 
Acharya Charaka has described it in the context of 
Sthaulya and has included Atisthoola Purusha in 
Ashtanindita Purush[1]. Overweight and obesity are 
major risk factors for a number of chronic diseases, 
including diabetes, cardiovascular diseases and 
hypertension. The prevalence of obesity has nearly 
tripled during the past 40 years worldwide[2]. An 
additional 39% of adults worldwide are overweight 
(BMI, 25 to 29). Once considered a problem only in 
high income countries, overweight and obesity are 
now dramatically on the rise in low and middle-
income countries, particularly in urban settings. 
According to the W.H.O., overweight and obesity are 
the fifth leading risk for global deaths[3]. Overweight 
and obesity are linked to more deaths worldwide 
than underweight. Globally there are more people 
who are obese than underweight and this occurs in 
every region except parts of sub-Saharan Africa and 
Asia. Obesity has taken place of an epidemic, still 
majority of people are not aware of the factors that 
welcomes this problem and the results that are 
obtained after one gets into this problem. 
Aims and Objectives of Study 
 Clinical evaluation of the efficacy of 
'Navakaguggulu' in the management of ‘Medoroga’ 
(Obesity). 
 Clinical evaluation of theefficacy of ‘Triphala 
Kwatha’ in the management of ‘Medoroga’ 
(Obesity). 
 To evaluate the combined efficacy of 
'Navakaguggulu' and ‘Triphala kwatha’ in the 
management of ‘Medoroga’ (Obesity). 
Ethical clearance: This study was approved by 
Institutional Ethical Committee (IEC) of National 
Institute of Ayurveda, Jaipur vide letter No.IEC 
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/ACA/2017/21; dated 26.04.2017, before starting 
the clinical trial on patients of Medoroga. 
Registration: This study was registered in Clinical 
Trial Registry of India (CTRI www.ctri.nic.in) with 
reference No– REF/2018/09/021609 
MATERIAL AND METHODS 
Selection of Case: The study was conducted on 30 
clinically diagnosed patients of ‘Medoroga’ (Obesity) 
selected from Arogyashala OPD & IPD of Department 
of Kayachikitsa, National Institute of Ayurveda, Jaipur 
(Rajasthan) and SSB Hospital, Jaipur. 
Inclusion Criteria 
 Patient willing to signature the consent form for 
the clinical trial. 
 The patients between the age group of 20 to 60 
years of age, irrespective of sex and socio-
economic status. 
 Patient having sign and symptoms of ‘Medoroga’ 
(Obesity). 
 Patient with BMI 30 or more.  
Exclusion Criteria  
 Patient not willing to signature the consent form 
for the clinical trial. 
 Patients with complicated and chronic disorder 
like Nephrotic syndrome, Hypothyroidism, 
Jaundice, Hepatitis, chronic infections and other 
serious diseases. 
 Patient having BMI below 30 and above 40.  
 Patient having obesity due to secondary reason 
such as drug induced or hormonal imbalance. 
 Pregnant women and lactating mothers. 
Criteria for Withdrawal 
 During the course of trial if any serious condition 
or any serious adverse effects occur which 
require urgent treatment. 
 Patients himself / herself want to withdraw from 
the clinical trial. 
Study Design: It was a single centre, Open label, 
Randomized, interventional, clinical trial. 
Administration of Drug: Clinically diagnosed and 
registered patients of ‘Medoroga’ (Obesity) were 
randomly divided into three groups. Each group had 
10 patients. 
Group A: 10 patients were treated with ‘Navaka 
Guggulu’ 2 tab (each tab of 500 mg) three times a day 
with lukewarm water for 30 days. 
Group B: 10 patients were treated with ‘Triphala 
Kwatha’ 50ml two times a day (morning and evening) 
for 30 days.  
Group C: 10 patients were treated with ‘Navaka 
Guggulu’ 2 tab (each tab. of 500 mg) three times a day 
with lukewarm water and ‘Triphala Kwatha’ 50ml 
two times a day (morning and evening) for 30 days. 
Preparation of Drugs 
Table 1: Contents of the ‘Navaka Guggulu[4] 
S. No. Drugs Latin Name Parts Used Quantity 
1. Shunthi Zingiber officinale Rhizome 1 Part 
2. Maricha Piper nigrum Fruit  1 Part 
3. Pippali Piper longum Fruit 1 Part 
4. Chitraka Plumbago zeylanica Root 1 Part 
5. Musta Cyperus rotundus Rhizome 1 Part 
6. Haritaki Terminalia chebula Fruit 1 Part 
7. Bibhitaka Terminalia bellirica Fruit 1 Part 
8. Amalaki Emblica officinalis Fruit 1 Part 
9. Vidanga Embelia ribes Fruit 1 Part 
10. Shuddha Guggulu Commiphora wightii Resin 9Part 
Table 2: Contents of Triphala Kwatha[5,6] (Kwatha Dravya – Yavakut) 
S.N. Drugs Latin Name Parts Used Quantity 
1. Haritaki Terminalia chebula Phala 1 Part 
2. Bibhitaka Terminalia bellirica Phala 1 Part 
3. Amalaki Emblica officinalis Phala 1 Part 
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Both of these drugs were prepared in GMP certified NIA Rasayanshala (Pharmacy) 
Method of Preparation of Trial Drugs 
Navaka Guggulu: After Shodhana, Sodhit guggulu 
was heated till it became thick liquid and was added 
with powder of above mentioned nine medicines 
which were taken in equal amount. Then it was 
mixed properly and was put out from flame and was 
stroked properly in Kharala or Kalwa yantra and the 
process was continued for few hours. Then 500mg 
Vati or tablets were made and were kept in air tight 
containers. 
Triphala Kwatha: 12gm of Triphalayavakuta churna 
was kept in a vessel with 200ml of water. Then it was 
boiled on slow flame (Mandaagnipaka) without 
covering the mouth of vessel and was reduced till 
quantity became 1/4 part i.e., 50ml. It was filtered 
with clean cotton cloth and filtered liquid was 
collected as Triphala kwatha. 
Dose 
Navaka Guggulu 2 tab (each tab of 500mg) with 
lukewarm water, three times a day for 30 days. 
Triphala Kwatha 50ml (prepared by 12gm of 
Kwatha Dravya) two times a day (morning and 
evening) for 30 days. 
Duration of Clinical Trial and Follow up Study 
Duration of trial - 30 days. 
Patients were followed up after 10days, after 20 days 
and after 30days. 
Criteria for Assessment 
During and after the trial patient were assessed on 
the following parameters 
Subjective Parameters 
All the registered patients of clinical trial were looked 
for any changes in their growing feeling of wellbeing 
or any improvement in the following sign and 
symptoms of Medoroga[7] (Obesity) after the course 
of therapy. 
For subjective parameters following sign and 
symptoms were assessed: 
1. Atikshudha (Excessive hunger) 
2. Atipipasa (Excessive thirst) 
3. Utsaha Hani (Lack of enthusiasm) 
4. Daurgandhya (Unpleasant body odour) 
5. Swedadhikya (Excessive sweating ) 
6. Daurbalya (Weakness) 
7. Gaurava (Heaviness of body) 
8. Kricchravyavayata (Difficulty in sexual 
intercourse) 
9. Alasya (Lethargy) 
10. Atinidra (Excessive sleep) 
11. UdarVriddhi (Bulging of abdomen) 
12. Sphiksthulata (Excessive fat accumulation in hip 
region ) 
13. Kshudraswasa (Dyspnoea on exertion) 
14. Ashaktahsarvakarmasu (Inability to work) 
Objective Parameters 
1. BMI (According to WHO classification) [8] 
2. Body weight 
3. Waist circumference[9] 
4. Waist-Hip ratio[10] 
5. Waist and Height ratio[11] 
Laboratory investigations 
1. Complete blood count 
2. Erythrocyte sedimentation Rate. 
3. Fasting blood sugar/ Random blood sugar 
4.  Lipid profile  
5.  RFT (Serumcreatinine and blood urea) 
6.  LFT (SGOT, SGPT and Sr. Bilirubin) 
7. Thyroid Profile (TSH)  
Routine Examination & Assessment 
The details of history and physical examination of 
patient were recorded as per the proforma. Clinical 
assessments were done on 1st day, after 10 days, 20 
days and 30 days. 
Assessment of Sign and Symptoms 
Assessment of sign and symptoms were done by 
using Symptoms Rating Scale as following: 
Table 3: Symptoms Rating Scale 
Sr. No. Severity Grading 
1.  Absent 0 
2.  Mild 1 
3.  Moderate 2 
4.  Severe 3 
5.  Very severe 4 
RESULTS 
All the results were calculated by using 
Software InStat GraphPad 3. For Nonparametric Data 
Wilcoxon matched-pairs signed ranks test is used 
while for Parametric Data Paired ‘t’ Test is used and 
results were calculated in each group. For calculating 
the inter group comparison, one way ANOVA Test 
and Unpaired 't' test were used for non-parametric 
and parametric data respectively. 
The results were considered as bellow.  
Insignificant/ Non significant: P >0.05  
Significant: P <0.05  
Highly significant: P < 0.01, P < 0.001, P<0.0001 
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Table 4: Effect of Therapy in Subjective Parameters (Wilcoxon matched paired signed ranks test) 
Sr.No. Symptoms Grou
p 
Mean Mean 
Diff. 
% 
Relief 
S.D. S.E. P Value S 
B.T. A.T. 
1 Atikshudha A 1.300 0.300 1.00 76.92 0.8165 0.2582 0.0078 HS 
B 1.000 0.500 0.500 50 0.5272 0.1667 0.0313 S 
C 1.200 0.500 0.700 58.33 0.4830 0.1528 0.0078 HS 
2 Atipipasa A 1.300 0.500 0.800 61.53 0.7888 0.2494 0.0126 S 
B 0.600 0.200 0.400 66.66 0.5164 0.1633 0.0625 NS 
C 0.900 0.400 0.500 55.55 0.5270 0.1667 0.0313 S 
3 Utsahahani A 1.000 0.600 0.400 40 0.5164 0.1633 0.0625 NS 
B 0.600 0.400 0.200 33.33 0.4216 0.1333 0.2500 NS 
C 0.700 0.200 0.500 71.42 0.5270 0.1667 0.0313 S 
4 Dourgandhya A 0.800 0.500 0.300 37.5 0.4830 0.1528 0.1250 NS 
B 0.400 0.100 0.300 75 0.4830 0.1528 0.1250 NS 
C 0.700 0.200 0.500 71.42 0.5270 0.1667 0.0313 S 
5 Gaurav A 1.100 0.300 0.800 72.72 0.9189 0.2906 0.0313 S 
B 1.200 0.500 0.700 58.33 0.6749 0.2134 0.0156 S 
C 1.300 0.600 0.700 53.84 0.4830 0.1528 0.0078 HS 
6 Swedadhikya A 0.800 0.500 0.300 37.5 0.4830 0.1528 0.1250 NS 
B 0.700 0.300 0.400 57.14 0.5164 0.1633 0.0625 NS 
C 1.000 0.400 0.600 60 0.6992 0.2211 0.0313 S 
7 Daurbalya A 0.400 0.100 0.300 75 0.4838 0.1528 0.1250 NS 
B 0.500 0.100 0.400 80 0.5164 0.1633 0.1250 NS 
C 0.900 0.100 0.800 88.88 0.6325 0.200 0.0078 HS 
8 Alasya A 1.000 0.300 0.700 70 0.8233 0.2603 0.0313 S 
B 0.700 0.500 0.200 28.57 0.4216 0.1333 0.250 NS 
C 0.900 0.100 0.800 88,88 0.6325 0.200 0.0078 HS 
9 Atinidra A 0.700 0.200 0.500 71.42 0.5270 0.1667 0.0313 S 
B 0.800 0.300 0.500 62.5 0.5270 0.1667 0.0313 S 
C 1.100 0.200 0.900 81.81 0.5676 0.1795 0.0039 HS 
10 Udaravriddhi A 2.100 1.300 0.800 38.09 0.4216 0.1333 0.0039 HS 
B 2.200 1.200 1.000 45.45 0.4714 0.1491 0.0020 HS 
C 2.100 1.000 1.100 52.38 0.3162 0.1000 0.0010 HS 
11 Sphiksthulata A 2.200 1.400 0.800 36.36 0.4216 0.1333 0.0039 HS 
B 2.200 1.200 1.000 45.45 0.4714 0.1491 0.0020 HS 
C 2.000 1.200 0.800 40 0.4216 0.1333 0.0039 HS 
12 Kshudrashwasa A 1,200 0.500 0.700 58.33 0.8233 0.2603 0.0313 S 
B 1.100 0.400 0.700 63.63 0.4830 0.1528 0.0078 HS 
C 1.100 0.600 0.500 45.45 0.5270 0.1667 0.0313 S 
13 Ashaktahsarvakar
masu 
A 0.700 0.200 0.500 71.42 0.5270 0.1667 0.0313 S 
B 0.500 0.200 0.300 60 0.4830 0.1528 0.1250 NS 
C 0.600 0.400 0.200 33.33 0.4216 0.1333 0.2500 NS 
14 Kricchavyavayata A 0.300 0.200 0.100 33.33 0.3162 0.100 0.500 NS 
B 0.200 0.100 0.100 50 0.3162 0.1000 0.50 NS 
C 0.200 0.100 0.100 50 0.3162 0.100 .50 NS 
(HS-Highlysignificant, S:significant, NS: Non-significant) 
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Table 5: Intergroup Comparison of Group A, Group B & Group C for Subjective Parameters: (K.W. Test) 
Sr.No. Symptoms K.W.Statistic P.Value Significance 
1 Atikshudha 2.488 0.2882 NS 
2 Atipipasa 1.563 0.4577 NS 
3 Utsahahani 1.943 0.3786 NS 
4 Dourgandhya 0.362, 2.030 NS 
5 Gaurav 0.1933 0.9079 NS 
6 Swedadhikya 1.058 0.5813 NS 
7 Daurbalya 0.9999 0.000 NS 
8 Alasya 4.803 0.906 NS 
9 Atinidra 4.110 0.1281 NS 
10 Udara vriddhi 4.581 0.1012 NS 
11 Sphiksthulta 0.000 0.9999 NS 
12 Kshudrashwasa 1.515 0.4689 NS 
13 Ashaktahsarvakarmasu 0.9206 0.6311 NS 
14 Kricchavyavayata 6032. 0.490 NS 
Table 6: Effect of Therapy in Anthropometric Parameters 
BMI= Body Mass Index, WC=Waist circumference, WHR=Waist hip Ratio, WHtR=Waist height Ratio 
Table 7: Showing Effect of Inter Group comparisons in Anthropometric Parameters (ANOVA test) 
Variable P-Value Significance 
BMI <0.0001 HS 
Body weight <0.0001 HS 
Waist Circumference 0.2853 NS 
Waist Hip Ratio 0.5422 NS 
Waist Height Ratio 0.3234 NS 
Table 8: Effect of Therapy in Objective Parameters: (One way ANOVA test) 
Variable Group 
Mean Mean 
Difference 
% 
Relief 
S.D. S.E. T Value 
P 
Value 
Sig 
B.T. A.T. 
Cholesterol 
A 210.94 202.08 8.860 4,21 24.298 7.684 1.153 0.1393 NS 
B 189.08 210.15 21.070 11.143 51.254 16.208 1.300 0.1130 NS 
C 186.64 183.23 3.410 1.827 36.554 11.560 0.2950 0.3873 NS 
TG 
A 165.40 123.41 41.990 25.38 42.023 13.289 3.160 0.0058 HS 
B 130.02 131.11 1.090 0.838 61.104 19.323 0.05641 0.4781 NS 
C 124.39 137.86 13.470 10.828 42.426 13.416 1.004 0.1708 NS 
HDL 
A 47.42 51.89 4.47 9.426 8.886 2.810 1.591 0.0731 NS 
B 54.780 59.020 4.240 7.740 15.653 4.950 0.8566 0.2070 NS 
C 48.430 46.710 1.720 3.551 14.820 4.687 0.3670 0.3610 NS 
 
 
Variable  Group 
Mean 
Mean Diff. 
% 
Relief 
S.D. S.E. P Value T 
Signifi
cance B.T. A.T. 
Weight 
A 83.900 82.340 1.560 1.859 0.5016 0.1586 <0.0001 9.836 HS 
B 81.500 79.210 2.290 2.809 0.4999 0.1581 0.0001 14.486 HS 
C 90.100 86.860 3.240 3.596 1.167 0.3691 0.0001 8.777 HS 
BMI 
A 34.002 33.372 0.6300 1.852 0.1925 0.06086 <0.0001 10.351 HS 
B 33.200 32.254 0.9460 2.849 0.2451 0.07752 0.0001 12.203 HS 
C 35.335 34.185 1.150 3.254 0.2427 0.07674 0.0001 14.986 HS 
WC 
A 99.000 98.111 1.556 1.571 0.5270 0.1757 0.0001 8.854 HS 
B 102.30 100.50 1.800 1.759 0.6325 0.2000 0.0001 9.000 HS 
C 109.30 107.00 2.300 2.104 1.418 0.4485 0.0033 5.129 HS 
WHR 
A 0.8940 0.8880 0.00600 0.671 0.00516 0.00163 0.0026 3.674 HS 
B 0.948 0.420 0006000 0.32 0008433 0.00266 .0255 2.20 S 
C 0.9520 0.9490 0.00300 0.3151 0.00483 0.00152 0.0406 1.964 S 
WHtR 
A 0.6250 0.6160 0.00900 1.44 0.00737 0.00233 0.0019 3.857 HS 
B 0..948 0.9420 0.00600 0.632 0.00843 0.00266 0.0255 2.250 S 
C 0.6560 0.6570 0.00100 0.152 0.02885 0.009123 0.1096 0.4576 NS 
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Table 9: Showing Effect of Inter Group comparisons of Objective Parameters 
Variable P- value Significance 
Serum Creatinine 0.3594 NS 
Cholesterol 0.0138 S 
Triglycerides 0.0333 S 
HDL 0.3218 NS 
DISCUSSION
Medoroga is described in Ayurveda under the 
caption of Santarpanottha Vikara (disease caused by 
over nourishment)[12]. Medodhatu is the site of 
metabolic disturbance in an obese individual. Meda 
increases due to excessive intake of Sneha and 
Madhurarasa[13]. Medoroga results due to 
Shleshmavardhaka ahara and Vihara, which causes 
production of Amarasa by suppressing Jatharagni. It 
further causes Medo-dhatvagnimandya, resulting in 
production of Amameda. It leads to excessive 
increase and accumulation of Medodhatu. It also 
causes Medovahasroto-sanga, which causes 
Margavrodha of vayu. These both factors lead to 
clinical presentation of Medoroga[14]. In the 
Samprapti of Medoroga, Kapha is main Dosha and 
Meda is main Dushya, while Agnimandya takes place 
at Medodhatvagni level[15]. Fortunately, the drugs 
Navaka Guggulu and Triphala kwatha fulfilled all 
these requirements. They helped in Samprapti-
vighatana of Medoroga either by their Rasa, Guna, 
Virya, Vipaka or Karma by acting at different levels 
i.e., Dosha, Dushya, Agni or Srotas and pacify the 
symptoms of Medoroga. 
The mode of action of Navaka Guggulu on Medoroga 
can be explainedas follows. 
On Dosha: Navaka Guggulu encounters Vata and 
Kapha Dosha by virtue of its Katu-Rasa dominance 
and Ushna-Virya. Vatahara action is also achieved by 
Snigdha property. 
On Dushya: Meda and Kleda are the chief culprits in 
Medoroga. Katu-Rasa performs Medo-Kleda 
upshoshana action. Sthairya Guna of Madhura Rasa 
combats Sharira Shaithilya. Ushna-Virya also helps in 
Kleda and Meda Vilayana action. 
On Agni & Ama: Katu-Rasa, Ushna-Virya encounters 
Dhatwagnimandya and potentiates the weakened 
Dhatwagni and help in Amapachana thereby 
alleviates Aparipakwa and Ama dhatu. 
On Srotas: Due to Katu-Rasa, all the involved 
channels are dilated i.e. “Srotansi Vivrunoti” action. 
Katu-Rasa and Ushna-Virya check over Medovaha and 
Mamsavaha Srotodushti. In nut cell in Navaka 
Guggulu, maximum ingredients have Katu Rasa, 
Laghu, Ruksha and Ushna Virya, Katu Vipaka, Vata-
Kaphashamaka, Karshana, Lekhaniya, Medorogahara, 
Amapachana, Dhatushoshana properties, which 
normalize the state of Agni. Thus, regulated 
Jatharagni, checked the excessive growth and 
accumulation of Medodhatu and thereby causing 
Lakshana Upshamana of disease Medoroga. This 
might be due to the Agnimahabhuta Pradhana 
(Su.Su.15/16) and Ushna, Virya, Dipana, Pachana 
effects of Navaka Guggulu as claimed by our classics. 
Charaka Samhita also described long-term of the 
treatment for the disease of Jirna and Atisthulata. 
Probable mode of action of Triphala Kwatha 
Triphala has Katu and Tikta rasa pradhana so 
it is Dipana, Pachana, Tridoshashamana as well as 
Lekhana by virtue. It has mild purgative action which 
causes Vata anulomana, therefore, it is one of the best 
natural colon cleansers that play key role in Vata 
pradhana samprapti vighatana in Kostha. It 
stimulates Jatharagni and regulates the metabolism 
in our body by Ama pachana, that encourage the 
digestive system to work efficiently so that the fat 
taken in food can be consumed in proper manner and 
no unnecessary storage of fat can take place in the 
body. Triphala acts as Rasayana also, which leads to 
formation of optimal Dhatu and protects the body 
from injury due to vitiated Dosha that improves 
blood circulation, and increases immunity. Thus the 
drug appeared successful in breaking the Dosha- 
Dushyasam murchana. A previous study has shown 
that Triphala contain Gallic acid, which is a widely 
occurring phenolic compound of plant origin. Gallic 
acid is selected as a bioactive marker due to its easy 
availability, common presence in these fruits and as 
anti-obesity property. Gallic acid is found maximum 
in Amalaki (Emblica officinalis)[16]. 
In the present study all the groups were 
found to be providing relief in majority of subjective 
parameters. The data and statistical analysis has 
shown that both of the drugs are potent in controlling 
the major sign and symptoms of Medoroga and also 
lowering the level of body mass index (BMI), waist 
hip ratio (WHR) and lipid profile. Group C treated 
with Navaka Guggulu and Triphala kwatha has 
produced best result in subjective parameters, than 
Group A and Group B treated with either Navaka 
Guggulu or Triphala Kwatha respectively. Although 
on inter group comparison there was no significant 
difference in response between the groups. In all 
Anthropometric parameters, Group A has shown best 
result followed by Group B and Group C while in lab 
parameters Group A has shown highly significant 
result in only Triglyceride level. Overall, Group C 
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provided better results in majority of the parameters 
as the vitiated Dosha got eliminated thereby 
absorbed drug performed their action of Samprapti 
Vighatana at cellular level. 
CONCLUSION 
It can be concluded that Navaka Guggulu and 
Triphala Kwatha both are effective, safe and 
economical alternative for the management of 
Medoroga. Compendium of the clinical contrive is 
that Navaka Guggulu and Triphala Kwatha might 
have additive effect and can be used in combination 
or separately as a safe and effective ‘Therapeutic 
Agents’ in the management of Medoroga. 
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